FGF21 and metabolic dysfunction-associated steatohepatitis: Because lipid accumulation, lipotoxicity, oxidative stress, and ER stress all appear to be fundamental drivers of NASH pathogenesis, FGF21-based therapies may be broadly useful in a potentially heterogeneous NASH patient population.